Literature DB >> 3104141

Vaccinia virus vectors utilizing the beta-galactosidase assay for rapid selection of recombinant viruses and measurement of gene expression.

D Panicali, A Grzelecki, C Huang.   

Abstract

Plasmids were constructed fusing vaccinia transcriptional regulatory sequences (promoters) to the lacZ gene of Escherichia coli. These recombinant plasmids were used to compare relative promoter strengths in transient expression assays and to construct recombinant vaccinia viruses producing beta-galactosidase (beta Gal). Viruses synthesizing beta Gal were determined by utilizing the chromogenic substrate, 5-bromo-4-chloro-3-indoyl-beta-D-galactoside to form blue plaques. A recombinant virus producing beta Gal was then used to select a second recombinant virus. This was accomplished via in vivo recombination replacing the lacZ gene with a sequence coding for the gp85 protein of Friend murine leukemia virus. The recombinant virus was selected by its inability to form blue plaques under appropriate conditions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3104141     DOI: 10.1016/0378-1119(86)90063-6

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  24 in total

1.  Genetic evidence for multiple nuclear functions of the herpes simplex virus ICP8 DNA-binding protein.

Authors:  M Gao; D M Knipe
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

2.  Transient dominant selection of recombinant vaccinia viruses.

Authors:  F G Falkner; B Moss
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

3.  Isolation and characterization of herpes simplex virus mutants containing engineered mutations at the DNA polymerase locus.

Authors:  A I Marcy; D R Yager; D M Coen
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

4.  Cloning and expression of foreign genes in vaccinia virus, using a host range selection system.

Authors:  M E Perkus; K Limbach; E Paoletti
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

5.  Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant.

Authors:  D J Goldstein; S K Weller
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

Review 6.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

7.  Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector.

Authors:  R Bernards; A Destree; S McKenzie; E Gordon; R A Weinberg; D Panicali
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

8.  Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals.

Authors:  P X Guo; S Goebel; S Davis; M E Perkus; B Languet; P Desmettre; G Allen; E Paoletti
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

9.  Isolation of a Marek's disease virus (MDV) recombinant containing the lacZ gene of Escherichia coli stably inserted within the MDV US2 gene.

Authors:  J L Cantello; A S Anderson; A Francesconi; R W Morgan
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

10.  Vaccinia virus-specific human CD4+ cytotoxic T-lymphocyte clones.

Authors:  R A Littaua; A Takeda; J Cruz; F A Ennis
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.